Analysts' Report Recap: Johnson & Johnson (NYSE:JNJ) – ExpertGazette

This post was originally published on this site

Johnson & Johnson (NYSE:JNJ) shares traded 0.36% up during most recent session to reach at the closing price of $123.64. The stock exchanged hands 3.99 Million shares versus average trading capacity of 6.22 Million shares, yielding a market cap of $333.07 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $129 within the next 52-weeks. The mean target projections are based on 18 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Johnson & Johnson (NYSE:JNJ) high price target of $140 and with a conservative view have low price target of $110.

Wells Fargo “Downgrades” Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on 1/26/17 to Market Perform with price target of $0.

Additionally on 11/29/16 Barclays “Downgrades” Johnson & Johnson (NYSE:JNJ) to Equal-Weight setting price target and on 9/13/16 Jefferies “Maintained” the stock to Hold. Furthermore on 8/04/16 Jefferies “Maintained” the stock to Hold.

On the other hand the company has Relative Strength Index (RSI 14) of 45.75 along with Average True Range (ATR 14) of 0.96, Consequently Johnson & Johnson (NYSE:JNJ)’s weekly and monthly volatility is 0.65%, 0.73% respectively. The company’s beta value is at 0.81.

In terms of Buy, Sell or Hold recommendations, Johnson & Johnson (NYSE:JNJ) has analysts’ mean recommendation of 2.5. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

Analysts who have weighed in on projected earnings growth are expecting that Johnson & Johnson (NYSE:JNJ) will report earnings of $1.78 for the current quarter on or around 7/18/17, however the company’s high EPS estimates are $1.86 and low estimates are $1.66. However the company reported $1.74 earnings per share for the same quarter during last year.

Previously Johnson & Johnson (NYSE:JNJ) reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.06. The company posted an earnings surprise of 3.4%.

While considering growth estimates of the company, it has next quarter growth estimates of 5.4% whereas during current quarter it has 2.3% estimations over growth, comparing to the estimations of 5.5% during current year and 8% for next year. Past 5 years growth of Johnson & Johnson (NYSE:JNJ) observed at 6.18%, looking forward for the next 5 years it has a strong prediction of 6.41% over growth.

Johnson & Johnson (NYSE:JNJ)’s revenue estimates for the current quarter are $18.95 Billion according to 16 number of analysts, for the current quarter the company has high revenue estimates of $19.28 Billion in contradiction of low revenue estimates of $18.65 Billion. For the current year the company’s revenue estimates are $75.64 Billion compared to low analyst estimates of $75.38 Billion and high estimates of $76.28 Billion according to 19 number of analysts.

Currently Johnson & Johnson (NYSE:JNJ)’s shares owned by insiders are 0.02%, whereas shares owned by institutional owners are 68.7%. However the six-month change in the insider ownership was recorded -20.36%, as well as three-month change in the institutional ownership was recorded -0.87%.

Johnson & Johnson (NYSE:JNJ) 52-week high price stands129.00 and low price stands108.60, its price distance from 52-week high is -4.16% while its distance from 52-week low price is 13.85%. The stock hit its 52-week high on 03/15/17, and 52-week low on 12/07/16. The company’s trailing twelve month income is 16.51 Billion dollars and is paying 2.72% dividend yield annually.

Johnson & Johnson (NYSE:JNJ)’s trailing twelve month revenues are $72.17 Billion, whereas its price to sales ratio for the same period is 4.64. Its book value per share for the most recent quarter is $25.99 while its price to book ratio for the same period is 4.76, as for as the company’s cash per share for the most recent quarter is $14.54, however its price to cash per share ratio for the same period is 8.51. The stock has 5 year expected PEG ratio of 3.24 whereas its trailing twelve month P/E ratio is 20.78.

This post was originally published on *this site*